Up­dat­ed: GSK's Vi­iV ex­pands li­cens­ing pact to in­clude long-act­ing HIV treat­ment

KI­GALI, RWAN­DA — Vi­iV Health­care, the HIV-fo­cused biotech that’s ma­jor­i­ty-owned by GSK, said it’s ex­pand­ing its vol­un­tary li­cens­ing agree­ment with the Med­i­cines Patent Pool and …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER